Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment ( <scp>AMELIO STUDY</scp> )
This study demonstrates that the fixed-dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction. The advantage of this fixed-dose combination is also considered to be very large.
Authors
- Masanori Yamazaki (ORCID: https://orcid.org/0000-0001-8817-8978)
- Mitsuhisa Komatsu (ORCID: https://orcid.org/0000-0002-1359-9732)
- Daisuke Takarabe
- Hisayuki Katsuyama (ORCID: https://orcid.org/0000-0003-2871-8340)
- Ryotaro Bouchi (ORCID: https://orcid.org/0000-0002-7664-4342)
- Hiroshi Kajio
- Toru Kitazawa
- Takahisa Tanaka (ORCID: https://orcid.org/0000-0001-6788-8436)
- Masahide Okamoto
- Mitsuhiko Noda
Institutions
- Suzuki (Japan) (JP)
- Shinshu University (JP)
- Saitama Prefecture (JP)
- National Center for Global Health and Medicine (JP)
- New Tokyo Hospital (JP)
- Hiroshima Kyoritsu Hospital (JP)
- Kumamoto Orthopedic Surgery Hospital (JP)
- Murayama Medical Center (JP)
- Toranomon Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1111/jdi.70253
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Center for Global Health and Medicine